RU2711442C2 - Соединения и способы - Google Patents

Info

Publication number

RU2711442C2

RU2711442C2 RU2017112989A RU2017112989A RU2711442C2 RU 2711442 C2 RU2711442 C2 RU 2711442C2 RU 2017112989 A RU2017112989 A RU 2017112989A RU 2017112989 A RU2017112989 A RU 2017112989A RU 2711442 C2 RU2711442 C2 RU 2711442C2

Authority

RU

Russia

Prior art keywords

damage

disease

disorder

nervous system

central nervous

Prior art date

2014-09-17

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 title claims description 161
• 238000000034 method Methods 0.000 title claims description 150
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 133
• 229940121836 Phosphodiesterase 1 inhibitor Drugs 0.000 claims abstract description 89
• 230000006378 damage Effects 0.000 claims abstract description 82
• 201000010099 disease Diseases 0.000 claims abstract description 73
• 208000035475 disorder Diseases 0.000 claims abstract description 59
• 210000000278 spinal cord Anatomy 0.000 claims abstract description 16
• 208000014674 injury Diseases 0.000 claims abstract description 15
• 208000027418 Wounds and injury Diseases 0.000 claims abstract description 12
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
• 210000004556 brain Anatomy 0.000 claims abstract description 10
• 208000015114 central nervous system disease Diseases 0.000 claims abstract description 7
• 230000003834 intracellular effect Effects 0.000 claims description 51
• 210000003169 central nervous system Anatomy 0.000 claims description 45
• 239000011575 calcium Substances 0.000 claims description 40
• 229910052791 calcium Inorganic materials 0.000 claims description 39
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 38
• 238000011282 treatment Methods 0.000 claims description 27
• 239000000203 mixture Substances 0.000 claims description 19
• 208000029028 brain injury Diseases 0.000 claims description 15
• 230000006931 brain damage Effects 0.000 claims description 13
• 231100000874 brain damage Toxicity 0.000 claims description 13
• 208000010412 Glaucoma Diseases 0.000 claims description 11
• 208000015122 neurodegenerative disease Diseases 0.000 claims description 9
• 239000000523 sample Substances 0.000 claims description 9
• 208000018737 Parkinson disease Diseases 0.000 claims description 7
• 206010061218 Inflammation Diseases 0.000 claims description 6
• 238000011161 development Methods 0.000 claims description 6
• 230000004054 inflammatory process Effects 0.000 claims description 6
• 201000006417 multiple sclerosis Diseases 0.000 claims description 6
• 230000004770 neurodegeneration Effects 0.000 claims description 6
• 230000002265 prevention Effects 0.000 claims description 6
• 206010028980 Neoplasm Diseases 0.000 claims description 5
• 239000012472 biological sample Substances 0.000 claims description 5
• 201000011510 cancer Diseases 0.000 claims description 5
• 238000005259 measurement Methods 0.000 claims description 5
• 210000002161 motor neuron Anatomy 0.000 claims description 5
• 208000024827 Alzheimer disease Diseases 0.000 claims description 4
• 206010012289 Dementia Diseases 0.000 claims description 4
• 208000015181 infectious disease Diseases 0.000 claims description 4
• 230000002401 inhibitory effect Effects 0.000 claims description 4
• 230000009885 systemic effect Effects 0.000 claims description 4
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
• 230000001684 chronic effect Effects 0.000 claims description 3
• 231100000317 environmental toxin Toxicity 0.000 claims description 3
• 238000001356 surgical procedure Methods 0.000 claims description 3
• 239000003053 toxin Substances 0.000 claims description 3
• 231100000765 toxin Toxicity 0.000 claims description 3
• 108700012359 toxins Proteins 0.000 claims description 3
• 206010003694 Atrophy Diseases 0.000 claims description 2
• 206010051288 Central nervous system inflammation Diseases 0.000 claims description 2
• 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims description 2
• 208000011990 Corticobasal Degeneration Diseases 0.000 claims description 2
• 208000024412 Friedreich ataxia Diseases 0.000 claims description 2
• 201000011240 Frontotemporal dementia Diseases 0.000 claims description 2
• 208000024777 Prion disease Diseases 0.000 claims description 2
• 206010057430 Retinal injury Diseases 0.000 claims description 2
• 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims description 2
• 230000037444 atrophy Effects 0.000 claims description 2
• 206010012601 diabetes mellitus Diseases 0.000 claims description 2
• 239000003937 drug carrier Substances 0.000 claims description 2
• 201000002491 encephalomyelitis Diseases 0.000 claims description 2
• 206010015037 epilepsy Diseases 0.000 claims description 2
• 208000008675 hereditary spastic paraplegia Diseases 0.000 claims description 2
• 230000002503 metabolic effect Effects 0.000 claims description 2
• 231100000878 neurological injury Toxicity 0.000 claims description 2
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
• 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 2
• 101001117089 Drosophila melanogaster Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1 Proteins 0.000 claims 1
• 206010002022 amyloidosis Diseases 0.000 claims 1
• 230000007613 environmental effect Effects 0.000 claims 1
• 230000000694 effects Effects 0.000 abstract description 29
• 239000003814 drug Substances 0.000 abstract description 21
• 239000000126 substance Substances 0.000 abstract description 10
• 238000001727 in vivo Methods 0.000 abstract description 2
• 230000002035 prolonged effect Effects 0.000 abstract 1
• 150000003839 salts Chemical class 0.000 description 42
• ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 description 31
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
• 101001117086 Dictyostelium discoideum cAMP/cGMP-dependent 3',5'-cAMP/cGMP phosphodiesterase A Proteins 0.000 description 27
• RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 26
• -1 noradrenergic Chemical compound 0.000 description 25
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 23
• 238000001819 mass spectrum Methods 0.000 description 23
• 239000003795 chemical substances by application Substances 0.000 description 22
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
• 230000001965 increasing effect Effects 0.000 description 20
• 208000028017 Psychotic disease Diseases 0.000 description 19
• 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 18
• 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 18
• 125000000217 alkyl group Chemical group 0.000 description 17
• 239000000543 intermediate Substances 0.000 description 15
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 14
• 210000004027 cell Anatomy 0.000 description 14
• 239000012043 crude product Substances 0.000 description 14
• 125000005843 halogen group Chemical group 0.000 description 14
• 210000001428 peripheral nervous system Anatomy 0.000 description 14
• 239000000651 prodrug Chemical class 0.000 description 14
• 229940002612 prodrug Drugs 0.000 description 14
• 230000002829 reductive effect Effects 0.000 description 14
• 230000008929 regeneration Effects 0.000 description 14
• 238000011069 regeneration method Methods 0.000 description 14
• 239000002904 solvent Substances 0.000 description 14
• 230000003376 axonal effect Effects 0.000 description 13
• 230000002708 enhancing effect Effects 0.000 description 13
• 239000000186 progesterone Substances 0.000 description 13
• 108090000623 proteins and genes Proteins 0.000 description 13
• 230000011664 signaling Effects 0.000 description 13
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
• 229960003387 progesterone Drugs 0.000 description 12
• 239000013543 active substance Substances 0.000 description 11
• 239000003153 chemical reaction reagent Substances 0.000 description 11
• 230000004410 intraocular pressure Effects 0.000 description 11
• 239000011541 reaction mixture Substances 0.000 description 11
• XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 10
• MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 10
• 230000005764 inhibitory process Effects 0.000 description 10
• 201000000980 schizophrenia Diseases 0.000 description 10
• 239000002253 acid Substances 0.000 description 9
• 229910052799 carbon Inorganic materials 0.000 description 9
• 238000006243 chemical reaction Methods 0.000 description 9
• 229940079593 drug Drugs 0.000 description 9
• 238000004128 high performance liquid chromatography Methods 0.000 description 9
• 102000004169 proteins and genes Human genes 0.000 description 9
• 230000019491 signal transduction Effects 0.000 description 9
• 239000007787 solid Substances 0.000 description 9
• 239000000243 solution Substances 0.000 description 9
• 239000000725 suspension Substances 0.000 description 9
• 208000011580 syndromic disease Diseases 0.000 description 9
• 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 8
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
• 102000004190 Enzymes Human genes 0.000 description 8
• 108090000790 Enzymes Proteins 0.000 description 8
• 241001465754 Metazoa Species 0.000 description 8
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
• 208000006011 Stroke Diseases 0.000 description 8
• 230000004913 activation Effects 0.000 description 8
• 229940088598 enzyme Drugs 0.000 description 8
• 230000000155 isotopic effect Effects 0.000 description 8
• 238000000746 purification Methods 0.000 description 8
• 208000028698 Cognitive impairment Diseases 0.000 description 7
• 206010026749 Mania Diseases 0.000 description 7
• 201000001880 Sexual dysfunction Diseases 0.000 description 7
• 125000004429 atom Chemical group 0.000 description 7
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
• 208000010877 cognitive disease Diseases 0.000 description 7
• 239000003085 diluting agent Substances 0.000 description 7
• 238000010438 heat treatment Methods 0.000 description 7
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
• 230000037041 intracellular level Effects 0.000 description 7
• 238000004519 manufacturing process Methods 0.000 description 7
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
• 210000002569 neuron Anatomy 0.000 description 7
• 239000000047 product Substances 0.000 description 7
• 231100000872 sexual dysfunction Toxicity 0.000 description 7
• GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 6
• MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 6
• PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 6
• 238000005481 NMR spectroscopy Methods 0.000 description 6
• 208000030886 Traumatic Brain injury Diseases 0.000 description 6
• HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
• 239000000460 chlorine Substances 0.000 description 6
• 230000001419 dependent effect Effects 0.000 description 6
• 230000012010 growth Effects 0.000 description 6
• 230000001404 mediated effect Effects 0.000 description 6
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
• 201000003631 narcolepsy Diseases 0.000 description 6
• 230000004766 neurogenesis Effects 0.000 description 6
• XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 6
• 229910000027 potassium carbonate Inorganic materials 0.000 description 6
• 229920006395 saturated elastomer Polymers 0.000 description 6
• 208000020431 spinal cord injury Diseases 0.000 description 6
• 125000001424 substituent group Chemical group 0.000 description 6
• 208000024891 symptom Diseases 0.000 description 6
• MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 6
• 230000009529 traumatic brain injury Effects 0.000 description 6
• ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 6
• DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
• ICISSZBYTVZMRU-UHFFFAOYSA-N 2-[4-(chloromethyl)phenyl]pyridine Chemical compound C1=CC(CCl)=CC=C1C1=CC=CC=N1 ICISSZBYTVZMRU-UHFFFAOYSA-N 0.000 description 5
• 208000020925 Bipolar disease Diseases 0.000 description 5
• 102100024316 Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A Human genes 0.000 description 5
• 102100024318 Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B Human genes 0.000 description 5
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 5
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
• 102000012749 Dopamine and cAMP-Regulated Phosphoprotein 32 Human genes 0.000 description 5
• 108010090047 Dopamine and cAMP-Regulated Phosphoprotein 32 Proteins 0.000 description 5
• 241000282412 Homo Species 0.000 description 5
• 101001117044 Homo sapiens Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A Proteins 0.000 description 5
• 101001117099 Homo sapiens Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B Proteins 0.000 description 5
• 102000004889 Interleukin-6 Human genes 0.000 description 5
• 108090001005 Interleukin-6 Proteins 0.000 description 5
• 108010037572 Type 1 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 5
• 210000001742 aqueous humor Anatomy 0.000 description 5
• 229910052786 argon Inorganic materials 0.000 description 5
• 125000003118 aryl group Chemical group 0.000 description 5
• 210000003050 axon Anatomy 0.000 description 5
• 230000008901 benefit Effects 0.000 description 5
• 230000015572 biosynthetic process Effects 0.000 description 5
• 229910052801 chlorine Inorganic materials 0.000 description 5
• 125000004122 cyclic group Chemical group 0.000 description 5
• 230000018109 developmental process Effects 0.000 description 5
• 235000019439 ethyl acetate Nutrition 0.000 description 5
• 239000003112 inhibitor Substances 0.000 description 5
• 230000031146 intracellular signal transduction Effects 0.000 description 5
• 210000001577 neostriatum Anatomy 0.000 description 5
• 210000004126 nerve fiber Anatomy 0.000 description 5
• 239000012074 organic phase Substances 0.000 description 5
• 210000001519 tissue Anatomy 0.000 description 5
• QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 4
• RQFCJASXJCIDSX-UHFFFAOYSA-N 14C-Guanosin-5'-monophosphat Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(O)=O)C(O)C1O RQFCJASXJCIDSX-UHFFFAOYSA-N 0.000 description 4
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
• XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 description 4
• VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
• 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 4
• 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 4
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
• 208000024254 Delusional disease Diseases 0.000 description 4
• 102000004076 Dopamine D1 Receptors Human genes 0.000 description 4
• 108090000511 Dopamine D1 Receptors Proteins 0.000 description 4
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 4
• 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 4
• 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 4
• HNHZSUMYHHGAQL-UHFFFAOYSA-N N1=C(C=CC=C1)C1=CC=C(CN2N=C3C(C(N(C=4N3CC(N=4)(C)C)C)=O)=C2Cl)C=C1 Chemical compound N1=C(C=CC=C1)C1=CC=C(CN2N=C3C(C(N(C=4N3CC(N=4)(C)C)C)=O)=C2Cl)C=C1 HNHZSUMYHHGAQL-UHFFFAOYSA-N 0.000 description 4
• 102000003923 Protein Kinase C Human genes 0.000 description 4
• 108090000315 Protein Kinase C Proteins 0.000 description 4
• QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 4
• 208000020186 Schizophreniform disease Diseases 0.000 description 4
• 102000010856 Type 1 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 4
• 230000001154 acute effect Effects 0.000 description 4
• OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
• 239000000556 agonist Substances 0.000 description 4
• 239000000908 ammonium hydroxide Substances 0.000 description 4
• 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 4
• 229960002470 bimatoprost Drugs 0.000 description 4
• AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 description 4
• 229960003679 brimonidine Drugs 0.000 description 4
• 230000003247 decreasing effect Effects 0.000 description 4
• VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
• 150000002148 esters Chemical class 0.000 description 4
• 229940011871 estrogen Drugs 0.000 description 4
• 239000000262 estrogen Substances 0.000 description 4
• 239000012065 filter cake Substances 0.000 description 4
• 238000001914 filtration Methods 0.000 description 4
• 239000012467 final product Substances 0.000 description 4
• 229910052731 fluorine Inorganic materials 0.000 description 4
• 239000011737 fluorine Substances 0.000 description 4
• RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 4
• LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 4
• 125000001072 heteroaryl group Chemical group 0.000 description 4
• 208000003532 hypothyroidism Diseases 0.000 description 4
• 230000002989 hypothyroidism Effects 0.000 description 4
• ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
• 210000002241 neurite Anatomy 0.000 description 4
• 229940054534 ophthalmic solution Drugs 0.000 description 4
• 239000002997 ophthalmic solution Substances 0.000 description 4
• KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
• 208000002851 paranoid schizophrenia Diseases 0.000 description 4
• 230000037361 pathway Effects 0.000 description 4
• RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 4
• 229960001416 pilocarpine Drugs 0.000 description 4
• 102000005962 receptors Human genes 0.000 description 4
• 108020003175 receptors Proteins 0.000 description 4
• 238000010992 reflux Methods 0.000 description 4
• 230000001105 regulatory effect Effects 0.000 description 4
• 208000022610 schizoaffective disease Diseases 0.000 description 4
• QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
• 239000007858 starting material Substances 0.000 description 4
• 238000003786 synthesis reaction Methods 0.000 description 4
• 229940124597 therapeutic agent Drugs 0.000 description 4
• FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
• RHNXMQLPXJSMON-UHFFFAOYSA-N 2-[4-(chloromethyl)phenyl]-6-fluoropyridine Chemical compound FC1=CC=CC(C=2C=CC(CCl)=CC=2)=N1 RHNXMQLPXJSMON-UHFFFAOYSA-N 0.000 description 3
• 102000003678 AMPA Receptors Human genes 0.000 description 3
• 108090000078 AMPA Receptors Proteins 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
• 201000000736 Amenorrhea Diseases 0.000 description 3
• 206010001928 Amenorrhoea Diseases 0.000 description 3
• 208000023275 Autoimmune disease Diseases 0.000 description 3
• VKXDBZLEZCBSHR-UHFFFAOYSA-N ClCC1=CC=C(C=C1)C1=NC=C(C=C1)F Chemical compound ClCC1=CC=C(C=C1)C1=NC=C(C=C1)F VKXDBZLEZCBSHR-UHFFFAOYSA-N 0.000 description 3
• 102000015554 Dopamine receptor Human genes 0.000 description 3
• 108050004812 Dopamine receptor Proteins 0.000 description 3
• 208000023105 Huntington disease Diseases 0.000 description 3
• 108010083674 Myelin Proteins Proteins 0.000 description 3
• 102000006386 Myelin Proteins Human genes 0.000 description 3
• MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
• 208000005793 Restless legs syndrome Diseases 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 3
• KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 3
• 239000005844 Thymol Substances 0.000 description 3
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
• 241001660687 Xantho Species 0.000 description 3
• BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 3
• PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
• 231100000540 amenorrhea Toxicity 0.000 description 3
• FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 3
• 229910000024 caesium carbonate Inorganic materials 0.000 description 3
• 150000001721 carbon Chemical group 0.000 description 3
• 125000004432 carbon atom Chemical group C* 0.000 description 3
• 230000015556 catabolic process Effects 0.000 description 3
• ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 3
• 238000011260 co-administration Methods 0.000 description 3
• 125000000753 cycloalkyl group Chemical group 0.000 description 3
• 238000006731 degradation reaction Methods 0.000 description 3
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
• 238000002875 fluorescence polarization Methods 0.000 description 3
• 230000006870 function Effects 0.000 description 3
• 125000001188 haloalkyl group Chemical group 0.000 description 3
• 125000000592 heterocycloalkyl group Chemical group 0.000 description 3
• 230000007062 hydrolysis Effects 0.000 description 3
• 238000006460 hydrolysis reaction Methods 0.000 description 3
• 230000001771 impaired effect Effects 0.000 description 3
• 208000000509 infertility Diseases 0.000 description 3
• 230000036512 infertility Effects 0.000 description 3
• 231100000535 infertility Toxicity 0.000 description 3
• 208000027866 inflammatory disease Diseases 0.000 description 3
• GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 description 3
• YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 3
• FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 3
• 230000009245 menopause Effects 0.000 description 3
• 238000011294 monotherapeutic Methods 0.000 description 3
• 210000005012 myelin Anatomy 0.000 description 3
• 210000003007 myelin sheath Anatomy 0.000 description 3
• 210000005036 nerve Anatomy 0.000 description 3
• 230000003018 neuroregenerative effect Effects 0.000 description 3
• 229910052757 nitrogen Inorganic materials 0.000 description 3
• 230000002093 peripheral effect Effects 0.000 description 3
• 208000033808 peripheral neuropathy Diseases 0.000 description 3
• 230000008569 process Effects 0.000 description 3
• 102000003998 progesterone receptors Human genes 0.000 description 3
• 108090000468 progesterone receptors Proteins 0.000 description 3
• 230000035755 proliferation Effects 0.000 description 3
• 150000003180 prostaglandins Chemical class 0.000 description 3
• LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 3
• 230000007781 signaling event Effects 0.000 description 3
• 238000006467 substitution reaction Methods 0.000 description 3
• 239000000758 substrate Substances 0.000 description 3
• 230000001225 therapeutic effect Effects 0.000 description 3
• 229960000790 thymol Drugs 0.000 description 3
• 230000008733 trauma Effects 0.000 description 3
• MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 description 3
• WFPIAZLQTJBIFN-DVZOWYKESA-N zuclopenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(Cl)=CC=C2SC2=CC=CC=C2/1 WFPIAZLQTJBIFN-DVZOWYKESA-N 0.000 description 3
• UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
• 229930182837 (R)-adrenaline Natural products 0.000 description 2
• IWEGDQUCWQFKHS-UHFFFAOYSA-N 1-(1,3-dioxolan-2-ylmethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN(CC2OCCO2)N=C1 IWEGDQUCWQFKHS-UHFFFAOYSA-N 0.000 description 2
• YRAJNWYBUCUFBD-UHFFFAOYSA-N 2,2,6,6-tetramethylheptane-3,5-dione Chemical compound CC(C)(C)C(=O)CC(=O)C(C)(C)C YRAJNWYBUCUFBD-UHFFFAOYSA-N 0.000 description 2
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
• AXNUZKSSQHTNPZ-UHFFFAOYSA-N 3,4-difluoroaniline Chemical compound NC1=CC=C(F)C(F)=C1 AXNUZKSSQHTNPZ-UHFFFAOYSA-N 0.000 description 2
• QWVQDAMZVZLFPB-UHFFFAOYSA-N 4-[(4-bromophenyl)methyl]-8,11,11-trimethyl-1,3,4,8,10-pentazatricyclo[7.3.0.02,6]dodeca-2,5,9-trien-7-one Chemical compound C1=C2C(=O)N(C)C3=NC(C)(C)CN3C2=NN1CC1=CC=C(Br)C=C1 QWVQDAMZVZLFPB-UHFFFAOYSA-N 0.000 description 2
• SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 2
• XNFGIXXZGYPLNJ-UHFFFAOYSA-N 5-methyl-2-[(4-pyridin-2-ylphenyl)methyl]-7H-pyrazolo[3,4-d]pyrimidine-4,6-dione Chemical compound CN1C(NC=2C(C1=O)=CN(N=2)CC1=CC=C(C=C1)C1=NC=CC=C1)=O XNFGIXXZGYPLNJ-UHFFFAOYSA-N 0.000 description 2
• BUFOYCZRAQRAJP-UHFFFAOYSA-N 8,11,11-trimethyl-1,3,4,8,10-pentazatricyclo[7.3.0.02,6]dodeca-2(6),4,9-trien-7-one Chemical compound O=C1N(C)C2=NC(C)(C)CN2C2=NNC=C21 BUFOYCZRAQRAJP-UHFFFAOYSA-N 0.000 description 2
• SIQHHHARVVFAQQ-UHFFFAOYSA-N 8,11,11-trimethyl-4-[(4-phenoxyphenyl)methyl]-1,3,4,8,10-pentazatricyclo[7.3.0.02,6]dodeca-2,5,9-trien-7-one Chemical compound C1=C2C(=O)N(C)C3=NC(C)(C)CN3C2=NN1CC(C=C1)=CC=C1OC1=CC=CC=C1 SIQHHHARVVFAQQ-UHFFFAOYSA-N 0.000 description 2
• 208000037853 Abnormal uterine bleeding Diseases 0.000 description 2
• 101150051188 Adora2a gene Proteins 0.000 description 2
• 201000005670 Anovulation Diseases 0.000 description 2
• 206010002659 Anovulatory cycle Diseases 0.000 description 2
• 208000019901 Anxiety disease Diseases 0.000 description 2
• 206010003805 Autism Diseases 0.000 description 2
• 208000020706 Autistic disease Diseases 0.000 description 2
• 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
• JDBOYLSLIQTNNH-UHFFFAOYSA-N COC1=CC=C(CN2C(N(C(C=3C2=NN(C=3)CC2=CC=C(C=C2)C2=NC=CC=C2)=O)C)=O)C=C1 Chemical compound COC1=CC=C(CN2C(N(C(C=3C2=NN(C=3)CC2=CC=C(C=C2)C2=NC=CC=C2)=O)C)=O)C=C1 JDBOYLSLIQTNNH-UHFFFAOYSA-N 0.000 description 2
• 102100024317 Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C Human genes 0.000 description 2
• 102000000584 Calmodulin Human genes 0.000 description 2
• 108010041952 Calmodulin Proteins 0.000 description 2
• 102000018208 Cannabinoid Receptor Human genes 0.000 description 2
• 108050007331 Cannabinoid receptor Proteins 0.000 description 2
• 206010007559 Cardiac failure congestive Diseases 0.000 description 2
• 208000024172 Cardiovascular disease Diseases 0.000 description 2
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
• HQRBEOJBYYXEGA-UHFFFAOYSA-N ClC=1N(C(C=2C(N=1)=NN(C=2)CC1=CC=C(C=C1)C1=NC=CC=C1)=O)C Chemical compound ClC=1N(C(C=2C(N=1)=NN(C=2)CC1=CC=C(C=C1)C1=NC=CC=C1)=O)C HQRBEOJBYYXEGA-UHFFFAOYSA-N 0.000 description 2
• 206010010904 Convulsion Diseases 0.000 description 2
• 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 2
• 108010003591 Cyclic GMP-Dependent Protein Kinases Proteins 0.000 description 2
• 102000004654 Cyclic GMP-Dependent Protein Kinases Human genes 0.000 description 2
• 102100020802 D(1A) dopamine receptor Human genes 0.000 description 2
• 102100020756 D(2) dopamine receptor Human genes 0.000 description 2
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
• 208000032131 Diabetic Neuropathies Diseases 0.000 description 2
• 102000004980 Dopamine D2 Receptors Human genes 0.000 description 2
• 108090001111 Dopamine D2 Receptors Proteins 0.000 description 2
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
• 208000012661 Dyskinesia Diseases 0.000 description 2
• 206010014733 Endometrial cancer Diseases 0.000 description 2
• 206010014759 Endometrial neoplasm Diseases 0.000 description 2
• 102000009025 Endorphins Human genes 0.000 description 2
• 108010049140 Endorphins Proteins 0.000 description 2
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
• JZWGOJWFNRWYJY-UHFFFAOYSA-N FC=1C=CC(=NC=1)C1=CC=C(CN2N=C3C(C(N(C=4N3CC(N=4)(C)C)C)=O)=C2CC)C=C1 Chemical compound FC=1C=CC(=NC=1)C1=CC=C(CN2N=C3C(C(N(C=4N3CC(N=4)(C)C)C)=O)=C2CC)C=C1 JZWGOJWFNRWYJY-UHFFFAOYSA-N 0.000 description 2
• PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 2
• 102000018899 Glutamate Receptors Human genes 0.000 description 2
• 108010027915 Glutamate Receptors Proteins 0.000 description 2
• 208000004547 Hallucinations Diseases 0.000 description 2
• 206010019280 Heart failures Diseases 0.000 description 2
• 206010019468 Hemiplegia Diseases 0.000 description 2
• 206010019909 Hernia Diseases 0.000 description 2
• 101001117094 Homo sapiens Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C Proteins 0.000 description 2
• 101000931925 Homo sapiens D(1A) dopamine receptor Proteins 0.000 description 2
• 101000931901 Homo sapiens D(2) dopamine receptor Proteins 0.000 description 2
• OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
• 206010020772 Hypertension Diseases 0.000 description 2
• 208000003618 Intervertebral Disc Displacement Diseases 0.000 description 2
• 206010050296 Intervertebral disc protrusion Diseases 0.000 description 2
• PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 2
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
• OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• 206010027339 Menstruation irregular Diseases 0.000 description 2
• CMFFRXAKDHYJMI-UHFFFAOYSA-N N1=C(C=CC=C1)C1=CC=C(CN2N=C3C(C(N(C=4N3CC(N=4)(C)C)C)=O)=C2)C=C1 Chemical compound N1=C(C=CC=C1)C1=CC=C(CN2N=C3C(C(N(C=4N3CC(N=4)(C)C)C)=O)=C2)C=C1 CMFFRXAKDHYJMI-UHFFFAOYSA-N 0.000 description 2
• UUDPSRGKDVVMSG-UHFFFAOYSA-N N1=C(C=CC=C1)C1=CC=C(CN2N=C3C(C(N(C=4N3CC(N=4)(C)C)C)=O)=C2NC2=CC(=C(C=C2)F)F)C=C1 Chemical compound N1=C(C=CC=C1)C1=CC=C(CN2N=C3C(C(N(C=4N3CC(N=4)(C)C)C)=O)=C2NC2=CC(=C(C=C2)F)F)C=C1 UUDPSRGKDVVMSG-UHFFFAOYSA-N 0.000 description 2
• UHBXCVVEFDTTRT-UHFFFAOYSA-N N1=C(C=CC=C1)C1=CC=C(CN2N=C3C(C(N(C=4N3CC(N=4)(C)C)C)=O)=C2NC2=CC=C(C=C2)F)C=C1 Chemical compound N1=C(C=CC=C1)C1=CC=C(CN2N=C3C(C(N(C=4N3CC(N=4)(C)C)C)=O)=C2NC2=CC=C(C=C2)F)C=C1 UHBXCVVEFDTTRT-UHFFFAOYSA-N 0.000 description 2
• 108020001621 Natriuretic Peptide Proteins 0.000 description 2
• 102000004571 Natriuretic peptide Human genes 0.000 description 2
• 208000012902 Nervous system disease Diseases 0.000 description 2
• 208000025966 Neurological disease Diseases 0.000 description 2
• 101800001814 Neurotensin Proteins 0.000 description 2
• 102000050267 Neurotensin Human genes 0.000 description 2
• 108010005298 Oligodendrocyte-Myelin Glycoprotein Proteins 0.000 description 2
• 102100026746 Oligodendrocyte-myelin glycoprotein Human genes 0.000 description 2
• 208000001132 Osteoporosis Diseases 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• 229910019213 POCl3 Inorganic materials 0.000 description 2
• RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• 108091000080 Phosphotransferase Proteins 0.000 description 2
• PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 2
• 208000005107 Premature Birth Diseases 0.000 description 2
• 206010036590 Premature baby Diseases 0.000 description 2
• 206010036618 Premenstrual syndrome Diseases 0.000 description 2
• 206010060862 Prostate cancer Diseases 0.000 description 2
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
• 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 2
• 206010039085 Rhinitis allergic Diseases 0.000 description 2
• 241000283984 Rodentia Species 0.000 description 2
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
• UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
• 208000000323 Tourette Syndrome Diseases 0.000 description 2
• 208000016620 Tourette disease Diseases 0.000 description 2
• 206010044565 Tremor Diseases 0.000 description 2
• 210000001766 X chromosome Anatomy 0.000 description 2
• 230000002159 abnormal effect Effects 0.000 description 2
• 229960000571 acetazolamide Drugs 0.000 description 2
• OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
• 229960004373 acetylcholine Drugs 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 229960005305 adenosine Drugs 0.000 description 2
• 239000000695 adrenergic alpha-agonist Substances 0.000 description 2
• 239000000674 adrenergic antagonist Substances 0.000 description 2
• 201000010105 allergic rhinitis Diseases 0.000 description 2
• 150000001414 amino alcohols Chemical class 0.000 description 2
• 229960003036 amisulpride Drugs 0.000 description 2
• NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 description 2
• 231100000552 anovulation Toxicity 0.000 description 2
• 239000005557 antagonist Substances 0.000 description 2
• 239000000935 antidepressant agent Substances 0.000 description 2
• 229940005513 antidepressants Drugs 0.000 description 2
• 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 2
• 239000000164 antipsychotic agent Substances 0.000 description 2
• 229940005529 antipsychotics Drugs 0.000 description 2
• 230000036506 anxiety Effects 0.000 description 2
• 150000004945 aromatic hydrocarbons Chemical group 0.000 description 2
• 125000001769 aryl amino group Chemical group 0.000 description 2
• 208000006673 asthma Diseases 0.000 description 2
• 239000003693 atypical antipsychotic agent Substances 0.000 description 2
• 229940127236 atypical antipsychotics Drugs 0.000 description 2
• 230000001363 autoimmune Effects 0.000 description 2
• 210000004227 basal ganglia Anatomy 0.000 description 2
• 102000012740 beta Adrenergic Receptors Human genes 0.000 description 2
• 108010079452 beta Adrenergic Receptors Proteins 0.000 description 2
• 125000002619 bicyclic group Chemical group 0.000 description 2
• 239000012148 binding buffer Substances 0.000 description 2
• 230000008499 blood brain barrier function Effects 0.000 description 2
• 210000001218 blood-brain barrier Anatomy 0.000 description 2
• 238000009835 boiling Methods 0.000 description 2
• 229960001724 brimonidine tartrate Drugs 0.000 description 2
• 229960000722 brinzolamide Drugs 0.000 description 2
• HCRKCZRJWPKOAR-JTQLQIEISA-N brinzolamide Chemical compound CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 HCRKCZRJWPKOAR-JTQLQIEISA-N 0.000 description 2
• 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 2
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
• 230000030833 cell death Effects 0.000 description 2
• 210000001638 cerebellum Anatomy 0.000 description 2
• 208000026106 cerebrovascular disease Diseases 0.000 description 2
• 238000002512 chemotherapy Methods 0.000 description 2
• 229960001076 chlorpromazine Drugs 0.000 description 2
• 210000004240 ciliary body Anatomy 0.000 description 2
• NJMYODHXAKYRHW-DVZOWYKESA-N cis-flupenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C2/1 NJMYODHXAKYRHW-DVZOWYKESA-N 0.000 description 2
• QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 2
• 230000003920 cognitive function Effects 0.000 description 2
• 239000006071 cream Substances 0.000 description 2
• 210000001947 dentate gyrus Anatomy 0.000 description 2
• 229910052805 deuterium Inorganic materials 0.000 description 2
• 238000010790 dilution Methods 0.000 description 2
• 239000012895 dilution Substances 0.000 description 2
• ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
• 229960003638 dopamine Drugs 0.000 description 2
• 229960000394 droperidol Drugs 0.000 description 2
• RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 description 2
• 201000003914 endometrial carcinoma Diseases 0.000 description 2
• 201000006828 endometrial hyperplasia Diseases 0.000 description 2
• 229960005139 epinephrine Drugs 0.000 description 2
• 229960005309 estradiol Drugs 0.000 description 2
• 229930182833 estradiol Natural products 0.000 description 2
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
• 229960002419 flupentixol Drugs 0.000 description 2
• 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
• BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
• 229930195712 glutamate Natural products 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 235000013928 guanylic acid Nutrition 0.000 description 2
• 230000002140 halogenating effect Effects 0.000 description 2
• 230000009931 harmful effect Effects 0.000 description 2
• VHHHONWQHHHLTI-UHFFFAOYSA-N hexachloroethane Chemical compound ClC(Cl)(Cl)C(Cl)(Cl)Cl VHHHONWQHHHLTI-UHFFFAOYSA-N 0.000 description 2
• 210000001320 hippocampus Anatomy 0.000 description 2
• 229940088597 hormone Drugs 0.000 description 2
• 239000005556 hormone Substances 0.000 description 2
• 238000002657 hormone replacement therapy Methods 0.000 description 2
• 229910052739 hydrogen Inorganic materials 0.000 description 2
• 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 2
• 239000000411 inducer Substances 0.000 description 2
• 230000001939 inductive effect Effects 0.000 description 2
• 230000002757 inflammatory effect Effects 0.000 description 2
• 238000002347 injection Methods 0.000 description 2
• 239000007924 injection Substances 0.000 description 2
• 230000004068 intracellular signaling Effects 0.000 description 2
• VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 2
• 238000002955 isolation Methods 0.000 description 2
• 229960001160 latanoprost Drugs 0.000 description 2
• 230000003902 lesion Effects 0.000 description 2
• UGVPKMAWLOMPRS-UHFFFAOYSA-M magnesium;propane;bromide Chemical compound [Mg+2].[Br-].CC[CH2-] UGVPKMAWLOMPRS-UHFFFAOYSA-M 0.000 description 2
• 230000007246 mechanism Effects 0.000 description 2
• 229910052751 metal Inorganic materials 0.000 description 2
• 239000002184 metal Substances 0.000 description 2
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
• 230000003228 microsomal effect Effects 0.000 description 2
• 239000000472 muscarinic agonist Substances 0.000 description 2
• 201000000585 muscular atrophy Diseases 0.000 description 2
• 239000000692 natriuretic peptide Substances 0.000 description 2
• 230000001537 neural effect Effects 0.000 description 2
• 210000004498 neuroglial cell Anatomy 0.000 description 2
• 230000007823 neuropathy Effects 0.000 description 2
• 201000001119 neuropathy Diseases 0.000 description 2
• 239000004090 neuroprotective agent Substances 0.000 description 2
• 230000000324 neuroprotective effect Effects 0.000 description 2
• PCJGZPGTCUMMOT-ISULXFBGSA-N neurotensin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 PCJGZPGTCUMMOT-ISULXFBGSA-N 0.000 description 2
• 230000007935 neutral effect Effects 0.000 description 2
• 230000002474 noradrenergic effect Effects 0.000 description 2
• 239000002674 ointment Substances 0.000 description 2
• 229940096984 ophthalmic cream Drugs 0.000 description 2
• 229940069265 ophthalmic ointment Drugs 0.000 description 2
• 239000002245 particle Substances 0.000 description 2
• 208000027232 peripheral nervous system disease Diseases 0.000 description 2
• 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 2
• 230000026731 phosphorylation Effects 0.000 description 2
• 238000006366 phosphorylation reaction Methods 0.000 description 2
• 102000020233 phosphotransferase Human genes 0.000 description 2
• PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 2
• 229960001697 physostigmine Drugs 0.000 description 2
• YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 description 2
• 230000035935 pregnancy Effects 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• 239000000583 progesterone congener Substances 0.000 description 2
• 238000011321 prophylaxis Methods 0.000 description 2
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 210000002307 prostate Anatomy 0.000 description 2
• 125000006239 protecting group Chemical group 0.000 description 2
• 239000003368 psychostimulant agent Substances 0.000 description 2
• 208000002815 pulmonary hypertension Diseases 0.000 description 2
• 125000004076 pyridyl group Chemical group 0.000 description 2
• 230000002285 radioactive effect Effects 0.000 description 2
• 239000011535 reaction buffer Substances 0.000 description 2
• 230000011514 reflex Effects 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 229940076279 serotonin Drugs 0.000 description 2
• 239000000741 silica gel Substances 0.000 description 2
• 229910002027 silica gel Inorganic materials 0.000 description 2
• 238000010898 silica gel chromatography Methods 0.000 description 2
• 208000019116 sleep disease Diseases 0.000 description 2
• 208000002320 spinal muscular atrophy Diseases 0.000 description 2
• 208000000995 spontaneous abortion Diseases 0.000 description 2
• 230000000638 stimulation Effects 0.000 description 2
• 229910052717 sulfur Inorganic materials 0.000 description 2
• 238000001308 synthesis method Methods 0.000 description 2
• 238000009121 systemic therapy Methods 0.000 description 2
• 238000004809 thin layer chromatography Methods 0.000 description 2
• 230000000699 topical effect Effects 0.000 description 2
• 229960002368 travoprost Drugs 0.000 description 2
• MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 2
• PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
• CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
• NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
• YUSCRGFYKCAQHE-HQFNMCNFSA-N (8r,9s,13s,14s,17s)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol;(8r,9s,13s,14s,16r,17r)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,16,17-triol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1.OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 YUSCRGFYKCAQHE-HQFNMCNFSA-N 0.000 description 1
• RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
• KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
• WSPOMRSOLSGNFJ-AUWJEWJLSA-N (Z)-chlorprothixene Chemical compound C1=C(Cl)C=C2C(=C/CCN(C)C)\C3=CC=CC=C3SC2=C1 WSPOMRSOLSGNFJ-AUWJEWJLSA-N 0.000 description 1
• IFLZPECPTYCEBR-VIEYUMQNSA-N (z)-but-2-enedioic acid;(2r)-3-(2-methoxyphenothiazin-10-yl)-n,n,2-trimethylpropan-1-amine Chemical compound OC(=O)\C=C/C(O)=O.C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1 IFLZPECPTYCEBR-VIEYUMQNSA-N 0.000 description 1
• YLRBJYMANQKEAW-UHFFFAOYSA-N 1-bromo-4-(bromomethyl)benzene Chemical compound BrCC1=CC=C(Br)C=C1 YLRBJYMANQKEAW-UHFFFAOYSA-N 0.000 description 1
• JQZAEUFPPSRDOP-UHFFFAOYSA-N 1-chloro-4-(chloromethyl)benzene Chemical compound ClCC1=CC=C(Cl)C=C1 JQZAEUFPPSRDOP-UHFFFAOYSA-N 0.000 description 1
• VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
• 238000005160 1H NMR spectroscopy Methods 0.000 description 1
• FCLQGHNSQXFQEG-UHFFFAOYSA-N 2-[4-(bromomethyl)phenyl]pyridine Chemical compound C1=CC(CBr)=CC=C1C1=CC=CC=N1 FCLQGHNSQXFQEG-UHFFFAOYSA-N 0.000 description 1
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
• PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 description 1
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
• 125000006281 4-bromobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Br)C([H])([H])* 0.000 description 1
• NYMDPDNETOLVBS-UHFFFAOYSA-N 4-fluoro-3-methylaniline Chemical compound CC1=CC(N)=CC=C1F NYMDPDNETOLVBS-UHFFFAOYSA-N 0.000 description 1
• KRZCOLNOCZKSDF-UHFFFAOYSA-N 4-fluoroaniline Chemical compound NC1=CC=C(F)C=C1 KRZCOLNOCZKSDF-UHFFFAOYSA-N 0.000 description 1
• MKLSFWUVWIXENK-UHFFFAOYSA-N 5-chloro-4-[[4-(5-fluoropyridin-2-yl)phenyl]methyl]-8,11,11-trimethyl-1,3,4,8,10-pentazatricyclo[7.3.0.02,6]dodeca-2,5,9-trien-7-one Chemical compound ClC1=C2C(=O)N(C)C3=NC(C)(C)CN3C2=NN1CC(C=C1)=CC=C1C1=CC=C(F)C=N1 MKLSFWUVWIXENK-UHFFFAOYSA-N 0.000 description 1
• AQOKCDNYWBIDND-ABRBVVEGSA-N 5-trans-17-phenyl trinor Prostaglandin F2alpha ethyl amide Chemical compound CCNC(=O)CCC\C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-ABRBVVEGSA-N 0.000 description 1
• JVYBHXSIAJRNGN-UHFFFAOYSA-N 7-[(4-methoxyphenyl)methyl]-5-methyl-1h-pyrazolo[3,4-d]pyrimidine-4,6-dione Chemical compound C1=CC(OC)=CC=C1CN1C(=O)N(C)C(=O)C2=C1NN=C2 JVYBHXSIAJRNGN-UHFFFAOYSA-N 0.000 description 1
• UNGDGQYONLTNJZ-UHFFFAOYSA-N 9-methoxy-9-borabicyclo[3.3.1]nonane Chemical compound C1CCC2CCCC1B2OC UNGDGQYONLTNJZ-UHFFFAOYSA-N 0.000 description 1
• AEOBEOJCBAYXBA-UHFFFAOYSA-N A2P5P Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1OP(O)(O)=O AEOBEOJCBAYXBA-UHFFFAOYSA-N 0.000 description 1
• 241000238876 Acari Species 0.000 description 1
• 206010002329 Aneurysm Diseases 0.000 description 1
• 206010002660 Anoxia Diseases 0.000 description 1
• 241000976983 Anoxia Species 0.000 description 1
• 102000004452 Arginase Human genes 0.000 description 1
• 108700024123 Arginases Proteins 0.000 description 1
• 206010061666 Autonomic neuropathy Diseases 0.000 description 1
• 208000006373 Bell palsy Diseases 0.000 description 1
• HASSSWFIYBIFLI-UHFFFAOYSA-N C(C)C=1N(N=C2C=1C(N(C=1N2CC(N=1)(C)C)C)=O)CC1=CC=C(C=C1)C1=NC(=CC=C1)F Chemical compound C(C)C=1N(N=C2C=1C(N(C=1N2CC(N=1)(C)C)C)=O)CC1=CC=C(C=C1)C1=NC(=CC=C1)F HASSSWFIYBIFLI-UHFFFAOYSA-N 0.000 description 1
• RLNORMSIPXNQRO-UHFFFAOYSA-N C(C=C/C(=O)O)(=O)O.C1=C(C)C=CC(C(C)C)=C1O Chemical compound C(C=C/C(=O)O)(=O)O.C1=C(C)C=CC(C(C)C)=C1O RLNORMSIPXNQRO-UHFFFAOYSA-N 0.000 description 1
• 102000004631 Calcineurin Human genes 0.000 description 1
• 108010042955 Calcineurin Proteins 0.000 description 1
• 102000003846 Carbonic anhydrases Human genes 0.000 description 1
• 108090000209 Carbonic anhydrases Proteins 0.000 description 1
• 102000014914 Carrier Proteins Human genes 0.000 description 1
• HFNMIXCYCKYLAO-UHFFFAOYSA-N ClC1=CC=C(CN2N=C3C(C(N(C=4N3CC(N=4)(C)C)C)=O)=C2NC2=CC=C(C=C2)F)C=C1 Chemical compound ClC1=CC=C(CN2N=C3C(C(N(C=4N3CC(N=4)(C)C)C)=O)=C2NC2=CC=C(C=C2)F)C=C1 HFNMIXCYCKYLAO-UHFFFAOYSA-N 0.000 description 1
• GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
• 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
• 102000004127 Cytokines Human genes 0.000 description 1
• 108090000695 Cytokines Proteins 0.000 description 1
• 101150049660 DRD2 gene Proteins 0.000 description 1
• MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 1
• 206010012335 Dependence Diseases 0.000 description 1
• HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
• 206010013033 Diplegia Diseases 0.000 description 1
• 229940098305 Dopamine D1 receptor agonist Drugs 0.000 description 1
• AQYGYDJZNNHNEU-UHFFFAOYSA-N FC1=CC=C(C=C1)NC=1N(N=C2C=1C(N(C=1N2CC(N=1)(C)C)C)=O)CC1=CC=C(C=C1)C1=NC(=CC=C1)F Chemical compound FC1=CC=C(C=C1)NC=1N(N=C2C=1C(N(C=1N2CC(N=1)(C)C)C)=O)CC1=CC=C(C=C1)C1=NC(=CC=C1)F AQYGYDJZNNHNEU-UHFFFAOYSA-N 0.000 description 1
• NOGNXFISZULWKY-UHFFFAOYSA-N FC1=CC=CC(=N1)C1=CC=C(CN2N=C3C(C(N(C=4N3CC(N=4)(C)C)C)=O)=C2CCC)C=C1 Chemical compound FC1=CC=CC(=N1)C1=CC=C(CN2N=C3C(C(N(C=4N3CC(N=4)(C)C)C)=O)=C2CCC)C=C1 NOGNXFISZULWKY-UHFFFAOYSA-N 0.000 description 1
• JLZVVIDQMULSIM-UHFFFAOYSA-N FC=1C=CC(=NC=1)C1=CC=C(CN2N=C3C(C(N(C=4N3CC(N=4)(C)C)C)=O)=C2CCC)C=C1 Chemical compound FC=1C=CC(=NC=1)C1=CC=C(CN2N=C3C(C(N(C=4N3CC(N=4)(C)C)C)=O)=C2CCC)C=C1 JLZVVIDQMULSIM-UHFFFAOYSA-N 0.000 description 1
• 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
• 108010072051 Glatiramer Acetate Proteins 0.000 description 1
• 206010018341 Gliosis Diseases 0.000 description 1
• 208000021965 Glossopharyngeal Nerve disease Diseases 0.000 description 1
• 102100022630 Glutamate receptor ionotropic, NMDA 2B Human genes 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
• 206010021143 Hypoxia Diseases 0.000 description 1
• 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
• 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
• 102000014150 Interferons Human genes 0.000 description 1
• 108010050904 Interferons Proteins 0.000 description 1
• 201000008450 Intracranial aneurysm Diseases 0.000 description 1
• 208000007623 Lordosis Diseases 0.000 description 1
• 206010027304 Menopausal symptoms Diseases 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
• DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
• 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
• 206010027926 Monoplegia Diseases 0.000 description 1
• 208000019430 Motor disease Diseases 0.000 description 1
• 208000016285 Movement disease Diseases 0.000 description 1
• 241000699660 Mus musculus Species 0.000 description 1
• 206010028289 Muscle atrophy Diseases 0.000 description 1
• 101000909851 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) cAMP/cGMP dual specificity phosphodiesterase Rv0805 Proteins 0.000 description 1
• 102100026933 Myelin-associated neurite-outgrowth inhibitor Human genes 0.000 description 1
• HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
• IUEKCYIGTAOMHJ-UHFFFAOYSA-N N1=C(C=CC=C1)C1=CC=C(CN2N=C3C(C(N(C=4N3CC(N=4)(C)C)C)=O)=C2NC2=CC(=C(C=C2)F)C)C=C1 Chemical compound N1=C(C=CC=C1)C1=CC=C(CN2N=C3C(C(N(C=4N3CC(N=4)(C)C)C)=O)=C2NC2=CC(=C(C=C2)F)C)C=C1 IUEKCYIGTAOMHJ-UHFFFAOYSA-N 0.000 description 1
• 108010025020 Nerve Growth Factor Proteins 0.000 description 1
• 102000007072 Nerve Growth Factors Human genes 0.000 description 1
• 206010029240 Neuritis Diseases 0.000 description 1
• ZNYOOJSUSHOBEK-UHFFFAOYSA-N OCC(C)(C)NC=1N(C(C=2C(N=1)=NN(C=2)CC1=CC=C(C=C1)C1=NC=CC=C1)=O)C Chemical compound OCC(C)(C)NC=1N(C(C=2C(N=1)=NN(C=2)CC1=CC=C(C=C1)C1=NC=CC=C1)=O)C ZNYOOJSUSHOBEK-UHFFFAOYSA-N 0.000 description 1
• 206010033892 Paraplegia Diseases 0.000 description 1
• 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 1
• 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
• 206010036105 Polyneuropathy Diseases 0.000 description 1
• 239000004793 Polystyrene Substances 0.000 description 1
• 206010062519 Poor quality sleep Diseases 0.000 description 1
• 241000097929 Porphyria Species 0.000 description 1
• 208000010642 Porphyrias Diseases 0.000 description 1
• 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
• 102000001253 Protein Kinase Human genes 0.000 description 1
• 206010063837 Reperfusion injury Diseases 0.000 description 1
• 108010038912 Retinoid X Receptors Proteins 0.000 description 1
• 208000008765 Sciatica Diseases 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• 239000000150 Sympathomimetic Substances 0.000 description 1
• GFBKORZTTCHDGY-UWVJOHFNSA-N Thiothixene Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2\C1=C\CCN1CCN(C)CC1 GFBKORZTTCHDGY-UWVJOHFNSA-N 0.000 description 1
• 208000036826 VIIth nerve paralysis Diseases 0.000 description 1
• FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 150000003926 acrylamides Chemical class 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 230000009692 acute damage Effects 0.000 description 1
• UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
• 108060000200 adenylate cyclase Proteins 0.000 description 1
• 102000030621 adenylate cyclase Human genes 0.000 description 1
• 210000004404 adrenal cortex Anatomy 0.000 description 1
• 239000000048 adrenergic agonist Substances 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 229930013930 alkaloid Natural products 0.000 description 1
• 125000002947 alkylene group Chemical group 0.000 description 1
• 102000030619 alpha-1 Adrenergic Receptor Human genes 0.000 description 1
• 108020004102 alpha-1 Adrenergic Receptor Proteins 0.000 description 1
• 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 description 1
• 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 description 1
• CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
• 239000002269 analeptic agent Substances 0.000 description 1
• 238000004458 analytical method Methods 0.000 description 1
• 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
• 230000007953 anoxia Effects 0.000 description 1
• 230000003042 antagnostic effect Effects 0.000 description 1
• 239000002518 antifoaming agent Substances 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 229960002610 apraclonidine Drugs 0.000 description 1
• IEJXVRYNEISIKR-UHFFFAOYSA-N apraclonidine Chemical compound ClC1=CC(N)=CC(Cl)=C1NC1=NCCN1 IEJXVRYNEISIKR-UHFFFAOYSA-N 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 150000004982 aromatic amines Chemical class 0.000 description 1
• 238000003556 assay Methods 0.000 description 1
• 238000003149 assay kit Methods 0.000 description 1
• 208000037875 astrocytosis Diseases 0.000 description 1
• 230000007341 astrogliosis Effects 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
• 239000002876 beta blocker Substances 0.000 description 1
• 229940097320 beta blocking agent Drugs 0.000 description 1
• 229940098085 betagan Drugs 0.000 description 1
• 229960004324 betaxolol Drugs 0.000 description 1
• CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 1
• 229940006072 bimatoprost ophthalmic solution Drugs 0.000 description 1
• 108091008324 binding proteins Proteins 0.000 description 1
• 230000000975 bioactive effect Effects 0.000 description 1
• 239000013060 biological fluid Substances 0.000 description 1
• 239000012620 biological material Substances 0.000 description 1
• 238000001574 biopsy Methods 0.000 description 1
• 239000004305 biphenyl Substances 0.000 description 1
• 235000010290 biphenyl Nutrition 0.000 description 1
• 210000004958 brain cell Anatomy 0.000 description 1
• 210000005013 brain tissue Anatomy 0.000 description 1
• 239000012267 brine Substances 0.000 description 1
• FFSAXUULYPJSKH-UHFFFAOYSA-N butyrophenone Chemical class CCCC(=O)C1=CC=CC=C1 FFSAXUULYPJSKH-UHFFFAOYSA-N 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• QGJOPFRUJISHPQ-NJFSPNSNSA-N carbon disulfide-14c Chemical compound S=[14C]=S QGJOPFRUJISHPQ-NJFSPNSNSA-N 0.000 description 1
• 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
• 239000003054 catalyst Substances 0.000 description 1
• 230000005779 cell damage Effects 0.000 description 1
• 208000037887 cell injury Diseases 0.000 description 1
• 210000000782 cerebellar granule cell Anatomy 0.000 description 1
• XMPZTFVPEKAKFH-UHFFFAOYSA-P ceric ammonium nitrate Chemical compound [NH4+].[NH4+].[Ce+4].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O XMPZTFVPEKAKFH-UHFFFAOYSA-P 0.000 description 1
• 239000013043 chemical agent Substances 0.000 description 1
• 229960001552 chlorprothixene Drugs 0.000 description 1
• 239000000544 cholinesterase inhibitor Substances 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 230000009693 chronic damage Effects 0.000 description 1
• 230000001886 ciliary effect Effects 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 229960004606 clomipramine Drugs 0.000 description 1
• 229960004170 clozapine Drugs 0.000 description 1
• 229940088505 compazine Drugs 0.000 description 1
• 230000006835 compression Effects 0.000 description 1
• 238000007906 compression Methods 0.000 description 1
• 230000003750 conditioning effect Effects 0.000 description 1
• 150000001879 copper Chemical class 0.000 description 1
• OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
• 230000001054 cortical effect Effects 0.000 description 1
• 239000007822 coupling agent Substances 0.000 description 1
• 210000003792 cranial nerve Anatomy 0.000 description 1
• 229960000860 dapsone Drugs 0.000 description 1
• 238000000354 decomposition reaction Methods 0.000 description 1
• 230000003412 degenerative effect Effects 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 238000010511 deprotection reaction Methods 0.000 description 1
• 229960003914 desipramine Drugs 0.000 description 1
• 229960000632 dexamfetamine Drugs 0.000 description 1
• 229940099238 diamox Drugs 0.000 description 1
• 150000001987 diarylethers Chemical class 0.000 description 1
• 125000005594 diketone group Chemical group 0.000 description 1
• OCUJLLGVOUDECM-UHFFFAOYSA-N dipivefrin Chemical compound CNCC(O)C1=CC=C(OC(=O)C(C)(C)C)C(OC(=O)C(C)(C)C)=C1 OCUJLLGVOUDECM-UHFFFAOYSA-N 0.000 description 1
• VKFAUCPBMAGVRG-UHFFFAOYSA-N dipivefrin hydrochloride Chemical compound [Cl-].C[NH2+]CC(O)C1=CC=C(OC(=O)C(C)(C)C)C(OC(=O)C(C)(C)C)=C1 VKFAUCPBMAGVRG-UHFFFAOYSA-N 0.000 description 1
• 229960000966 dipivefrine Drugs 0.000 description 1
• 239000000510 dopamine 1 receptor stimulating agent Substances 0.000 description 1
• 230000008923 dopaminergic innervation Effects 0.000 description 1
• 229960003933 dorzolamide Drugs 0.000 description 1
• IAVUPMFITXYVAF-XPUUQOCRSA-N dorzolamide Chemical compound CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 IAVUPMFITXYVAF-XPUUQOCRSA-N 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 229960004679 doxorubicin Drugs 0.000 description 1
• 206010013663 drug dependence Diseases 0.000 description 1
• 230000009977 dual effect Effects 0.000 description 1
• 239000012636 effector Substances 0.000 description 1
• 210000004696 endometrium Anatomy 0.000 description 1
• 229940008359 estradiol / estriol Drugs 0.000 description 1
• 229940086018 estradiol / progesterone Drugs 0.000 description 1
• 239000003687 estradiol congener Substances 0.000 description 1
• PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
• 229960001348 estriol Drugs 0.000 description 1
• 230000012173 estrus Effects 0.000 description 1
• 210000000720 eyelash Anatomy 0.000 description 1
• 239000000835 fiber Substances 0.000 description 1
• 229960000556 fingolimod Drugs 0.000 description 1
• KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 1
• 238000003818 flash chromatography Methods 0.000 description 1
• 229960002464 fluoxetine Drugs 0.000 description 1
• 229960002690 fluphenazine Drugs 0.000 description 1
• 235000019253 formic acid Nutrition 0.000 description 1
• 239000012634 fragment Substances 0.000 description 1
• 210000003736 gastrointestinal content Anatomy 0.000 description 1
• 229940003380 geodon Drugs 0.000 description 1
• 229960003776 glatiramer acetate Drugs 0.000 description 1
• 201000005442 glossopharyngeal neuralgia Diseases 0.000 description 1
• 229940095895 haldol Drugs 0.000 description 1
• 229910052736 halogen Inorganic materials 0.000 description 1
• 229960003878 haloperidol Drugs 0.000 description 1
• 230000000971 hippocampal effect Effects 0.000 description 1
• 230000009808 hippocampal neurogenesis Effects 0.000 description 1
• 235000012907 honey Nutrition 0.000 description 1
• 150000004677 hydrates Chemical class 0.000 description 1
• IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
• 150000002430 hydrocarbons Chemical group 0.000 description 1
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
• 229960004801 imipramine Drugs 0.000 description 1
• BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
• 230000028993 immune response Effects 0.000 description 1
• 229960003444 immunosuppressant agent Drugs 0.000 description 1
• 239000003018 immunosuppressive agent Substances 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 230000004941 influx Effects 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 229940079322 interferon Drugs 0.000 description 1
• 229940100601 interleukin-6 Drugs 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 208000028867 ischemia Diseases 0.000 description 1
• 230000000302 ischemic effect Effects 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 210000003140 lateral ventricle Anatomy 0.000 description 1
• IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 description 1
• 229960000831 levobunolol Drugs 0.000 description 1
• DNTDOBSIBZKFCP-YDALLXLXSA-N levobunolol hydrochloride Chemical compound [Cl-].O=C1CCCC2=C1C=CC=C2OC[C@@H](O)C[NH2+]C(C)(C)C DNTDOBSIBZKFCP-YDALLXLXSA-N 0.000 description 1
• 238000012417 linear regression Methods 0.000 description 1
• 230000006742 locomotor activity Effects 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• 210000005171 mammalian brain Anatomy 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 230000013011 mating Effects 0.000 description 1
• 230000010534 mechanism of action Effects 0.000 description 1
• 238000002483 medication Methods 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 229960001252 methamphetamine Drugs 0.000 description 1
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
• 229940042053 methotrimeprazine Drugs 0.000 description 1
• 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
• 229960001344 methylphenidate Drugs 0.000 description 1
• 239000003604 miotic agent Substances 0.000 description 1
• 125000002950 monocyclic group Chemical group 0.000 description 1
• 201000005518 mononeuropathy Diseases 0.000 description 1
• 238000010172 mouse model Methods 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 230000020763 muscle atrophy Effects 0.000 description 1
• 210000002464 muscle smooth vascular Anatomy 0.000 description 1
• 206010028417 myasthenia gravis Diseases 0.000 description 1
• 208000010125 myocardial infarction Diseases 0.000 description 1
• 210000004165 myocardium Anatomy 0.000 description 1
• 229960005027 natalizumab Drugs 0.000 description 1
• 230000017997 negative regulation of axon regeneration Effects 0.000 description 1
• 210000000653 nervous system Anatomy 0.000 description 1
• 208000004296 neuralgia Diseases 0.000 description 1
• 230000000626 neurodegenerative effect Effects 0.000 description 1
• 230000001272 neurogenic effect Effects 0.000 description 1
• 230000007511 neuronal proliferation Effects 0.000 description 1
• 230000002981 neuropathic effect Effects 0.000 description 1
• 208000021722 neuropathic pain Diseases 0.000 description 1
• 230000004112 neuroprotection Effects 0.000 description 1
• 230000035771 neuroregeneration Effects 0.000 description 1
• 125000004433 nitrogen atom Chemical group N* 0.000 description 1
• 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
• 210000004940 nucleus Anatomy 0.000 description 1
• KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
• 210000001706 olfactory mucosa Anatomy 0.000 description 1
• 210000002475 olfactory pathway Anatomy 0.000 description 1
• 210000004248 oligodendroglia Anatomy 0.000 description 1
• 229940100654 ophthalmic suspension Drugs 0.000 description 1
• 239000006186 oral dosage form Substances 0.000 description 1
• 229940109739 orap Drugs 0.000 description 1
• 229910052760 oxygen Inorganic materials 0.000 description 1
• 229960001057 paliperidone Drugs 0.000 description 1
• YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
• 239000000734 parasympathomimetic agent Substances 0.000 description 1
• 230000001499 parasympathomimetic effect Effects 0.000 description 1
• 229940005542 parasympathomimetics Drugs 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 229960000761 pemoline Drugs 0.000 description 1
• NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 1
• 229960000762 perphenazine Drugs 0.000 description 1
• 239000012071 phase Substances 0.000 description 1
• 229940107333 phenergan Drugs 0.000 description 1
• 150000002990 phenothiazines Chemical class 0.000 description 1
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 235000021317 phosphate Nutrition 0.000 description 1
• 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
• 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 230000007084 physiological dysfunction Effects 0.000 description 1
• 229960003634 pimozide Drugs 0.000 description 1
• 230000007824 polyneuropathy Effects 0.000 description 1
• 229920002223 polystyrene Polymers 0.000 description 1
• 230000004911 positive regulation of CREB transcription factor activity Effects 0.000 description 1
• 230000015284 positive regulation of neurogenesis Effects 0.000 description 1
• 210000002442 prefrontal cortex Anatomy 0.000 description 1
• 238000002360 preparation method Methods 0.000 description 1
• 230000037452 priming Effects 0.000 description 1
• WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 1
• 229960003111 prochlorperazine Drugs 0.000 description 1
• DSKIOWHQLUWFLG-SPIKMXEPSA-N prochlorperazine maleate Chemical compound [H+].[H+].[H+].[H+].[O-]C(=O)\C=C/C([O-])=O.[O-]C(=O)\C=C/C([O-])=O.C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 DSKIOWHQLUWFLG-SPIKMXEPSA-N 0.000 description 1
• 150000003146 progesterones Chemical class 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 201000008752 progressive muscular atrophy Diseases 0.000 description 1
• 230000000770 proinflammatory effect Effects 0.000 description 1
• 229960003910 promethazine Drugs 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 229940127293 prostanoid Drugs 0.000 description 1
• 150000003814 prostanoids Chemical class 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 108060006633 protein kinase Proteins 0.000 description 1
• 229960002601 protriptyline Drugs 0.000 description 1
• BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 description 1
• 208000020016 psychiatric disease Diseases 0.000 description 1
• 125000003226 pyrazolyl group Chemical group 0.000 description 1
• 238000010791 quenching Methods 0.000 description 1
• 229960004431 quetiapine Drugs 0.000 description 1
• URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
• ZTHJULTYCAQOIJ-WXXKFALUSA-N quetiapine fumarate Chemical compound [H+].[H+].[O-]C(=O)\C=C\C([O-])=O.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 ZTHJULTYCAQOIJ-WXXKFALUSA-N 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 239000003642 reactive oxygen metabolite Substances 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 230000001172 regenerating effect Effects 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 208000023504 respiratory system disease Diseases 0.000 description 1
• 210000003994 retinal ganglion cell Anatomy 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
• HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 1
• 229950005741 rolipram Drugs 0.000 description 1
• 229930195734 saturated hydrocarbon Natural products 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 230000028327 secretion Effects 0.000 description 1
• 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
• 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
• 238000011894 semi-preparative HPLC Methods 0.000 description 1
• 229940035004 seroquel Drugs 0.000 description 1
• 229960002073 sertraline Drugs 0.000 description 1
• VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
• 230000001568 sexual effect Effects 0.000 description 1
• 208000020685 sleep-wake disease Diseases 0.000 description 1
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
• 239000012453 solvate Substances 0.000 description 1
• 239000011877 solvent mixture Substances 0.000 description 1
• 230000003595 spectral effect Effects 0.000 description 1
• VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical group COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 1
• 210000001032 spinal nerve Anatomy 0.000 description 1
• 102000009076 src-Family Kinases Human genes 0.000 description 1
• 108010087686 src-Family Kinases Proteins 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 238000003756 stirring Methods 0.000 description 1
• 208000011117 substance-related disease Diseases 0.000 description 1
• 239000011593 sulfur Substances 0.000 description 1
• 230000008093 supporting effect Effects 0.000 description 1
• 238000011477 surgical intervention Methods 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 230000001975 sympathomimetic effect Effects 0.000 description 1
• 229940064707 sympathomimetics Drugs 0.000 description 1
• 238000010189 synthetic method Methods 0.000 description 1
• 239000003826 tablet Substances 0.000 description 1
• 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 238000012360 testing method Methods 0.000 description 1
• CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• 125000001113 thiadiazolyl group Chemical group 0.000 description 1
• 125000004014 thioethyl group Chemical group [H]SC([H])([H])C([H])([H])* 0.000 description 1
• 229960002784 thioridazine Drugs 0.000 description 1
• 150000005075 thioxanthenes Chemical class 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 238000013518 transcription Methods 0.000 description 1
• 230000035897 transcription Effects 0.000 description 1
• 238000011830 transgenic mouse model Methods 0.000 description 1
• 229940113006 travatan Drugs 0.000 description 1
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
• 206010044652 trigeminal neuralgia Diseases 0.000 description 1
• 229960004317 unoprostone Drugs 0.000 description 1
• TVHAZVBUYQMHBC-SNHXEXRGSA-N unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O TVHAZVBUYQMHBC-SNHXEXRGSA-N 0.000 description 1
• 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
• 230000003827 upregulation Effects 0.000 description 1
• 230000002747 voluntary effect Effects 0.000 description 1
• 230000003313 weakening effect Effects 0.000 description 1
• 229940002639 xalatan Drugs 0.000 description 1
• 229960000607 ziprasidone Drugs 0.000 description 1
• 229960004141 zuclopenthixol Drugs 0.000 description 1